Skip to main content
. 2020 Oct 23;121(1):1–21. doi: 10.1007/s00421-020-04516-0

Table 4.

Summary of studies investigating the effects of energy availability on markers of bone metabolism

Study LEA induction method Population LEA duration (days) EI EEE EA Exercise mode Dietary composition
(Pro, CHO, Fat %)
Bone formation markers Bone resorption markers
Ihle and Loucks (2004) REI and EX (3 × 2 Exp. Design) Y, SED (N = 29 F) 5 25, 35, 45 and 60 15 10, 20, 30 and 45 Uphill walking @ 70% VO2max 15, 57 and 28%

Linear ↓ in P1CP as EA decreased

Curvilinear ↓ in OC, greatest between 30 – 20 LEA treatments

NTx ↑ in 10 LEA condition
Papageorgiou et al (2017) REI and EX Y, ACTIVE (N = 22; 11 M, 11 F) 5 30 and 60 15 15 and 45 Running @ 70% VO2max  ~ 18, 48 and 34%

P1NP ↓ in F during LEA, ⟷ in M

⟷ in Sclerostin between conditions in M or F

β-CTX ↑ in F during LEA, ⟷ in M
Papageorgiou et al (2018) REI Only; EX only Y, ACTIVE (N = 10 F) 3 15, 45 and 45 0, 30 and 0 5, 15 and 45 Running @ 70% VO2max (LEA (EX) only) 20, 50 and 30% P1NP ↓ in LEA (Diet) compared to CON ⟷ in β-CTX
Murphy and Koehler (2020) REI only Y, RT (N = 7; 5 M, 2 F) 3 15, 15 and 40

0 (days 1—2)

REX on day 3 (EEE NR)

0, 0 and 40 5 × 5 Back Squats @ ~ 1 RIR

38, 50, 12% (LEA)

14, 60, 26% (NEA)

⟷ in P1NP

↑ Sclerostin prior to REX bout, restored post-REX

NA

A graphical summary of the contents of the table can be seen in Fig. 3

Arrows represent changes in groups with low energy availability (typically lower than 40–45 kcal/kg lean body mass/day)

EA energy availability, LEA low energy availability, EI energy intake, EEE exercise energy expenditure, CHO carbohydrates, PRO protein, M male, F female, ET endurance-trained, NA not assessed, NEA normal energy availability, REI reduced energy intake, REX resistance exercise, RT resistance-trained, Y young, P1CP carboxy-terminal propeptide of type 1 procollagen, P1NP N-terminal propeptide of type 1 procollagen, NTx aminoterminal telopeptide of type 1 collagen, β-CTX C-terminal telopeptide of type 1 collagen, OC Osteocalcin